Different Gene Between Different TKIs Effection
Conditions
Brief summary
We performed targeted-capture sequencing of 127 known and putative cancer-related genes of patients who best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs by next-generation sequencing (NGS) .
Interventions
GENETICdifferent effection
Analysis of the reasons for treatment
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
1. Chronic myeloid leukemia-Chronic phase(CML-CP) patients treated with receiveTyrosine kinase inhibitor -TKI(including imatinib, dasatinib and nilotinib) for more than 1 years 2. best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs according to Q-pcr detected BCR/ABL(IS) in peripheral blood and hematologic response and cytogenetic response 3. Informed consent of the patient or his legal representative
Exclusion criteria
1. Patients had history of CML-AP or CML-BC 2. CML Patients who have received allogeneic hematopoietic stem cell transplantation 3. CML Patients who have received immunotherapy (except interferon, including car-t and other cellular immunotherapy) 4. Woman who is pregnant or nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cancer-associated gene mutations in CML treatment with TKIs by NGS | 1 year after TKI treatment | We performed targeted-capture sequencing of 127 known and putative cancer-related genes of patients who best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs by next-generation sequencing (NGS) |
Countries
China
Contacts
Primary Contactxu na, doctor
Outcome results
None listed